NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I basically agree with you wrt the GBM indication and that BP would pay a nice sum for NWBO based on an approved DCVax-L indication. I think they would only pay a modest premium on top of that for future indications, but I think that more or less aligns with your valuations ($25-30B or so?).

Disagree with the current status of mRNAs though. The article you linked states that they were having success after the early years. And it lists 22 active mRNA vaccine oncology trials.

One interesting trial (wrt the relationship with DCVax-L) is DEN-STEM Phase 2 trial in nGBM. For the mRNA component it amplifies the mRNA from the extracted tumor.

I am a bit surprised that they would take an aggressive tactic in not using adjuvant temozolomide in the treatment arm (only in the SOC arm). This trial is for methylated only, where the chemo has the most benefit.

Not at all implying this is a "threat" to DCVax-L in any way. Just one to watch to see what happens.